Phase 2 Leukaemia Trial, Recruiting NCT02143830 Sponsor: Children's Hospital Medical Center, Cincinnati Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT02143830
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Fanconi anemia.
  • People who have one of the following blood-related conditions: (1) Severe Aplastic Anemia (very low bone marrow activity) or a severe drop in one type of blood cell, along with very low platelet counts, very low white blood cell counts, or very low red blood cell counts (or dependence on blood transfusions); (2) Myelodysplastic Syndrome (MDS), a condition where the bone marrow doesn't produce enough healthy blood cells; or (3) Acute Myelogenous Leukemia (a type of blood cancer), whether untreated, in remission, or with disease that has returned or not responded to treatment.
  • People whose bone marrow donor is either an unrelated donor who is a close tissue-type (HLA) match, or a related donor who is a tissue-type match — but not a fully matched sibling.
  • People of any gender or ethnic background.
  • People with a general health and activity level score above 70% on standard medical performance scales (confirm with trial site).
  • People whose heart is functioning well enough — either no symptoms, or test results showing the heart is pumping adequately (confirm with trial site for specific measurements).
  • People whose liver enzyme levels and bilirubin (a liver marker) are within acceptable ranges (confirm with trial site for specific measurements).
  • People whose kidney function is within acceptable ranges based on blood tests or kidney filtration rate (confirm with trial site for specific measurements).
  • People whose lungs are functioning well enough — either no symptoms, or lung capacity test results above a minimum level (confirm with trial site).
  • People who are willing to take part as a research participant and sign a consent form.
  • Female patients and female donors who are not pregnant or breastfeeding at the time of signing consent, and who agree to pregnancy testing before the transplant and to avoiding pregnancy during the study.

Who may not be able to join:

  • People whose leukemia has spread to the central nervous system (brain and spinal cord).
  • Female patients who are pregnant or breastfeeding.
  • People who have an active infection (viral, bacterial, or fungal) that is not under control.
  • People who test positive for HIV-I/II or HTLV-I/II (certain viral infections).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Parinda Mehta, MD, CCHMC

Phone: (513)803-1102

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2014
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Graft Failure or Rejection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov